Evidence map›Paper›PMID 42662231›Full record

ReviewBiodesign research2026

Advances in prime editing: Molecular innovations, Large-fragment engineering, and AI-driven design.

Waqar Muhammad, Xi Cao, Aziz Umar, Khan Nauman, Ziao Jiao, Junjie Liu, Xiaolong Wang, Kun Xu

Abstract readReview
In one paragraph

Review in Biodesign research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Waqar MuhammadHainan Institute of Northwest A&F University, Sanya, Hainan, 572025, China.
Xi CaoHainan Institute of Northwest A&F University, Sanya, Hainan, 572025, China.
Aziz UmarCollege of Animal Science and Technology, Northwest A&F University, No.3 Taicheng Road, Yangling, Shaanxi, 712100, China.
Khan NaumanCollege of Animal Science and Technology, Northwest A&F University, No.3 Taicheng Road, Yangling, Shaanxi, 712100, China.
Ziao JiaoCollege of Agronomy, Northwest A&F University, No.3 Taicheng Road, Yangling, Shaanxi, 712100, China.
Junjie LiuCollege of Agronomy, Northwest A&F University, No.3 Taicheng Road, Yangling, Shaanxi, 712100, China.
Xiaolong WangHainan Institute of Northwest A&F University, Sanya, Hainan, 572025, China.
Kun XuHainan Institute of Northwest A&F University, Sanya, Hainan, 572025, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Prime editing has rapidly emerged as a versatile and precise genome engineering technology capable of introducing targeted substitutions, insertions, and deletions without requiring double-strand breaks or donor DNA templates. Since its initial development, substantial progress has been achieved through iterative innovations in core components, including Cas protein variants, reverse transcriptase engineering, and prime editing guide RNA (pegRNA) design. These advancements have significantly improved editing efficiency, fidelity, and target accessibility across diverse biological systems. In parallel, the development of large-fragment editing platforms such as TwinPE, PASTE, and PrimeRoot has expanded the scope of prime editing from small sequence modifications to kilobase-scale genome rewriting. Furthermore, the integration of artificial intelligence-driven design tools has transformed pegRNA optimisation and system selection, enabling more predictable and efficient editing outcomes. This review provides a comprehensive overview of recent molecular innovations, large-fragment editing strategies, and computational approaches shaping the evolution of prime editing. Collectively, these developments position prime editing as a highly programmable and scalable platform with broad applications in medicine, agriculture, and synthetic biology.

Indexed as

Cas9 nickLarge-fragment prime editingpegRNA engineeringPE variantsPrime editingReverse transcriptase

Identifiers

PMID42662231
PMCPMC13520094

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.